Literature DB >> 18982467

Internal radiotherapy using 32P colloid or microsphere for refractory solid tumors.

Wen Gao1, Lu Liu, Gao-Jun Teng, Guo-Sheng Feng, Guan-Sheng Tong, Nai-Rong Gao.   

Abstract

OBJECTIVE: The aim of this work was to study the effectiveness of 32P colloids or microspheres, by arterial interventional administration or stromal injection in the treatment of refractory solid tumors.
METHODS: By arterial intervention, under the guidance of computerized tomography, X-ray, ultrasonogram, or under direct vision of the surgical field, 32P microspheres (259-685 MBq) or radioactive colloid (281-666 MBq) was administered to 60 cases with refractory solid tumors. Tumor inhibition rate, side effects, survival period, and so on were observed.
RESULTS: The tumor growth was obviously inhibited after the intratumoral injection of 32P colloid. The average survival time in the 60 cases was 35 months with a high tumor inhibition rate (93.4%). Thirty-one cases were completely relieved (51.7%), and 25 cases achieved partial remission (PR, 41.7%). One case with right lobe hepatocellular carcinoma has survived 90 months. The drug was ineffective only in four cases, including one patient who died of gastrointestinal hemorrhage and three of hepatic failure. No other obvious side effects were observed. Intratumoral necrosis, intense fibrosis in the tumor mass, and an integrated capsule encompassing the tumor were revealed by histological examination.
CONCLUSIONS: Arterial interventional administration or stromal injection with 32P microspheres or colloid revealed a very fair clinical effectiveness in the treatment of refractory solid tumors. The range of safe effective dosage for 32P glass microspheres and 32P chromic phosphate in one treatment course is 555-740 MBq and 185-370 MBq, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18982467     DOI: 10.1007/s12149-008-0176-6

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  6 in total

1.  Safety evaluation of 32P-chromic phosphate-poly L lactic acid particles interstitially implanted into livers of Beagle dogs.

Authors:  Lu Liu; Peilin Huang; Qi Nie; Benzhong Qi; Qinghua Wu; Hailin Gao; Zexuan Yang; Daming Chen
Journal:  Cancer Biother Radiopharm       Date:  2012-02-08       Impact factor: 3.099

2.  Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide.

Authors:  J Tyler French; Beth Goins; Marcela Saenz; Shihong Li; Xavier Garcia-Rojas; William T Phillips; Randal A Otto; Ande Bao
Journal:  J Vasc Interv Radiol       Date:  2010-05-15       Impact factor: 3.464

Review 3.  Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.

Authors:  Yu-Ping Xu; Min Yang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

4.  Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol.

Authors:  Shahram Akhlaghpoor; Alireza Aziz-Ahari; Mahasti Amoui; Shahnaz Tolooee; Hossein Poorbeigi; Shahab Sheybani
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

5.  Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (¹³¹I-GMSs) following intratumoral injection.

Authors:  Chuan-Chao Li; Jun-Lin Chi; Yu Ma; Jian-Hong Li; Chuan-Qin Xia; Lin Li; Zhuo Chen; Xiao-Li Chen
Journal:  Radiat Oncol       Date:  2014-06-23       Impact factor: 3.481

Review 6.  Radiopharmaceutical therapy in cancer: clinical advances and challenges.

Authors:  George Sgouros; Lisa Bodei; Michael R McDevitt; Jessie R Nedrow
Journal:  Nat Rev Drug Discov       Date:  2020-07-29       Impact factor: 84.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.